In the immune system, the data support the model shown in Fig. 5, in which electrophilic NRF2 activators induce a unique gene expression profile in immune cells which functions to augment anti-cancer immunity through multiple parallel processes, and thus represents a novel immunotherapy which would complement existing immune checkpoint inhibitor drugs. The gene discussed is NFE2L2; the disease is cancer.